Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | AURKA | O14965 | 2/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
| ▸ | IKBKB | O14920 | 1/20 | 0.41 |
| ▸ | CHUK | O15111 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 7/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 5/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2891862 | 1.00 | GAA (0.46) | GAAHPGDMAPK1AURKAAURKB | |
| SCHEMBL5551067 | 0.83 | IKBKB (0.52) | GAAHPGDMAPK1KIF11IKBKB | |
| SCHEMBL8277193 | 0.78 | ALDH1A1 (0.53) | GAAHPGDMAPK1KIF11EPHX2 | |
| SCHEMBL7691873 | 0.78 | GAA (0.50) | GAAHPGDMAPK1KIF11EPHX2 | |
| SCHEMBL1016072 | 0.78 | ACLY (0.58) | GAAHPGDMAPK1KIF11EPHX2 | |
| SCHEMBL2893505 | 0.77 | LMNA (0.49) | GAAPPARG | |
| SCHEMBL2893503 | 0.77 | LMNA (0.49) | GAAPPARG | |
| SCHEMBL1016778 | 0.76 | POLB (0.55) | GAAHPGDMAPK1AURKAAURKB | |
| SCHEMBL2891864 | 0.75 | GAA (0.47) | GAAHPGDMAPK1KIF11EPHX2 | |
| SCHEMBL13719816 | 0.75 | EPHX2 (0.52) | GAAHPGDMAPK1EPHX2NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286391-A1 | NOVEL PROCESSES FOR THE PREPARATION OF CYCLOPROPYL-AMIDE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-11 | — | — | US | claimed |
| US-7795426-B2 | Processes for the preparation of cyclopropyl-amide derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-14 | — | — | US | claimed |
| EP-1951699-A2 | PROCESSES FOR THE PREPARATION OF CYCLOPROPYL-AMIDE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-06 | — | — | EP | claimed |
| US-20070129351-A1 | NOVEL PROCESSES FOR THE PREPARATION OF CYCLOPROPYL-AMIDE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-06-07 | — | — | US | claimed |
| WO-2007053386-A2 | PROCESSES FOR THE PREPARATION OF CYCLOPROPYL-AMIDE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-10 | — | — | WO | claimed |
| US-7687492-B2 | 1,2,4-Oxadiazole derivatives as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME CORP. (US) | 2010-03-30 | — | — | US | disclosed |
| US-20080021009-A1 | 1,2,4-Oxadiazole Derivatives as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | MERCK SHARP & DOHME LLC | 2008-01-24 | — | — | US | disclosed |
| EP-1756074-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | Merck & Co., Inc. (US) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005108382-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO., INC. (US) | 2005-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286391-A1 | NOVEL PROCESSES FOR THE PREPARATION OF CYCLOPROPYL-AMIDE DERIVATIVES | HRH4, HRH2, HRH1 | GAA 1163/4885HPGD 300/4885MAPK1 3408/4885 |
| US-20070129351-A1 | NOVEL PROCESSES FOR THE PREPARATION OF CYCLOPROPYL-AMIDE DERIVATIVES | HRH4, HRH2, HRH1 | GAA 1163/4885HPGD 300/4885MAPK1 3408/4885 |
| US-20080021009-A1 | 1,2,4-Oxadiazole Derivatives as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | DPP4, DPP3, DPP7 | GAA 223/4885HPGD 765/4885MAPK1 3390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.